Program |
Wednesday, November 22, 2017 | |||
09:00 - 09:05 | Welcome and introduction [More Info] Speaker: Marinus Lobbezoo, Congress by design, Harmelen, The Netherlands | ||
09:05 - 10:00 | A1. Cancer and cancer therapeutics [More Info] Speaker: Rob Berg, INC Research, Amsterdam, The Netherlands | ||
10:00 - 11:15 | A2. Carcinogenesis & tumor cell biology [More Info] Speaker: Jos Jonkers, The Netherlands Cancer Institute, Amsterdam, The Netherlands | ||
11:15 - 11:30 | Break | ||
11:30 - 12:30 | A3. Oncopathology: Diagnosing cancer [More Info] Speaker: Paul van Diest, University Medical Center, Utrecht, The Netherlands | ||
12:30 - 13:30 | Lunch | ||
13:30 - 14:45 | A4. Essentials of medical oncology [More Info] Speaker: Jan Vermorken, Antwerp University Hospital, Edegem, Belgium | ||
14:50 - 16:05 | A5. Essentials of hemato-oncology [More Info] Speaker: Marie José Kersten, Hematologist, Academic Medical Center, Amsterdam, The Netherlands | ||
16:05 - 16:30 | Break | ||
16:30 - 17:45 | A6. Essentials of cancer immunotherapy [More Info] Speaker: Christian Blank, Netherlands Cancer Institute, Amsterdam The Netherlands | ||
17:45 - 18:00 | Q&A day 1 overall | Evaluation day 1 | ||
18:00 - 19:00 | Welcome drinks (complimentary drinks in hotel bar) | ||
Thursday, November 23, 2017 | |||
09:00 - 09:45 | B1. Drug discovery and preclinical drug testing [More Info] Speaker: Michel Janicot, JMI ONConsulting, Brussels, Belgium | ||
09:45 - 10:30 | B2. Preclinical toxicology of anticancer agents (including introduction group exercise) [More Info] Speaker: Benno Rattel, Amgen, Munich, Germany | ||
10:30 | Coffee served [More Info] | ||
10:30 - 11:15 | Group exercise preclinical toxicology | Plenary discussion of group exercise preclinical toxicology | ||
11:15 - 12:25 | B3. Phase I clinical studies with single agents (including introduction group exercise) [More Info] Speaker: Ferry Eskens, Erasmus MC, Rotterdam, The Netherlands | ||
12:25 - 13:15 | Lunch | ||
13:15 - 14:00 | Group exercise phase I studies | Plenary discussion of group exercise phase I studies | ||
14:00 - 15:00 | B4. Phase I clinical studies with combinations of agents [More Info] Speaker: Udai Banerji, The Institute of Cancer Research, London, United Kingdom | ||
15:00 - 15:20 | Break | ||
15:20 - 16:10 | B5. Biomarkers in oncology drug development [More Info] Speaker: Alain van Gool, Radboud University Medical Center, Nijmegen, The Netherlands | ||
16:10 - 17:00 | B6. Development of companion diagnostics for cancer therapeutics [More Info] Speaker: Martina Kaufmann, Martina Kaufmann Strategic Consulting, Muellheim, Germany | ||
17:00 - 17:20 | Q&A with Prof. van Gool and Dr. Kaufmann | ||
17:20 - 17:30 | Q&A day 2 overall | Evaluation day 2 | ||
17:30 | End of day 2 / Evening free | ||
Friday, November 24, 2017 | |||
09:00 - 10:00 | B7. The regulatory environment for anticancer drug development [More Info] Speaker: Adriaan Fruijtier, CATS Consultants, Dietmannsried, Germany | ||
10:00 - 10:15 | Break | ||
10:15 - 10:45 | B8.1. Biostatistical considerations in oncology clinical trials (Part 1): Early- phase trials [More Info] Speaker: Lucinda Billingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom | ||
10:45 - 11:45 | B9. Post-registration drug development in oncology [More Info] Speaker: Eric Hoedemaker, Novartis, The Netherlands | ||
11:45 - 11:55 | Mini-break | ||
11:55 - 12:40 | B8.2. Biostatistical considerations in oncology clinical trials (Part 2): Late phase trials [More Info] Speaker: Lucinda Billingham, Institute of Cancer and Genomic Sciences, Birmingham, United Kingdom | ||
12:40 - 13:30 | Lunch | ||
13:30 - 15:00 | B10. Full clinical development of cancer therapeutics (including introduction group exercise) [More Info] Speaker: Eric van der Putten, Aglaia Biomedical Ventures, Bilthoven, The Netherlands | ||
15:00 - 15:15 | Break | ||
15:15 - 16:00 | Group exercise full clinical development | Plenary discussion of group exercise full clinical development | ||
16:00 - 16:30 | Closing: Take home messages & overall evaluation [More Info] Speaker: Eric van der Putten, Aglaia Biomedical Ventures, Bilthoven, The Netherlands | ||
16:30 | Adjourn |